“We have seen remarkable results from clinical trials using AAV vectors for AADC gene transfer,” says Shin-ichi Muramatsu, a pioneer of AAV vector research, and a professor in Jichi Medical ...

More than two years after its approval in Europe, PTC Therapeutics' gene therapy for rare genetic disorder AADC deficiency will soon be made available to patients in the US. The FDA has approved ...

The FDA granted accelerated approval to eladocagene exuparvovec (Kebilidi) to treat children and adults with aromatic L-amino acid decarboxylase (AADC) deficiency, the agency announced Thursday.

Researchers are enhancing the best features of AAV capsids and overcoming their limitations to accelerate gene-based therapies.

Medscape Neurology, March 15, 2010 AADC Gene Therapy for Parkinson's Disease In this video blog, Dr. Kapil D. Sethi discusses a recent study exploring the efficacy, safety, and tolerability of ...

Expert Rev Neurother. 2013;13(6):695-705. Gene therapy using neurotrophic factors is the most promising disease-modifying approach for Parkinson's disease. The strong safety profile and rapidly ...